Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
about
Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancerConstitutional promoter methylation and risk of familial melanomaRegulation of cancer germline antigen gene expression: implications for cancer immunotherapy.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesOverexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy targetThe SSX family of cancer-testis antigens as target proteins for tumor therapy.Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur womenA potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy.Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implicationsCancer/testis antigens and urological malignanciesDe novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repairHuman rhabdomyosarcoma cells express functional pituitary and gonadal sex hormone receptors: Therapeutic implications.Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status.Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.Expression of cancer/testis antigens is correlated with improved survival in glioblastoma.HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significancePRAME expression and promoter hypomethylation in epithelial ovarian cancer.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.The biology of cancer testis antigens: putative function, regulation and therapeutic potentialRequisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.Cancer testis antigens: a novel target in lung cancer.Epigenetics of melanoma: implications for immune-based therapies.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients.Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis.Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.Improving cancer immunotherapy with DNA methyltransferase inhibitors.Tumour heterogeneity: principles and practical consequences.Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
P2860
Q24338624-71F6E2E0-3AC3-4B71-A10B-880721C4A0FAQ33555751-51D9EBDD-2927-4743-976B-8C0D2FCE8088Q33715446-59B6A4C1-EDD8-4532-9144-42559D5F5C2AQ33779164-96E5BAF1-744D-4ADD-A53A-FB6BD1D391E0Q33957165-08390753-8211-467E-9093-11A45539DD9EQ33980682-403D12AF-D1F3-4D45-8B86-BBE960C5954AQ34029028-AB839D9F-5B98-4C25-A683-883547696DB1Q34146229-AFF44B24-7720-46EA-81CA-071CCD8C8B15Q34425118-5B3F7079-B2BD-49E6-A8E6-F5BC1F9C0C32Q35968482-8A55915F-F23E-4C17-8803-AB2351C2B170Q36060324-A2250526-9D58-4A38-BF14-5604D2E246B1Q36075245-1D466A3E-88F9-4F8B-8B7B-E9E3C59E7BB4Q36136992-6D877459-E7BA-47DA-A1E7-A26FAF3B6D4BQ36287972-F2163076-E455-46FB-888B-4BC57D8C33E9Q36337004-1264AB6B-8CDD-448E-B4F9-F52C582F3343Q36459332-C27423C1-3FE1-41C7-B8ED-C6CF79A97DD9Q36605340-FC2B7F4D-20BC-456C-B42D-E40ECE140B95Q36734191-83AE16B3-6656-4430-9E0D-089C7A931981Q36761134-D4688FF6-DEB5-42EE-A4C2-A69120282068Q36786757-2DE10E05-3E8B-47B0-BB46-9190ABDF8FD4Q36801625-DB920E8E-7610-497D-BA34-A51D91577A95Q37038420-BF2A483F-1607-4B87-890D-8229B0EFF640Q37287152-2E16D061-53A3-4995-AB6C-EB32D86CF9F6Q37564420-9FE08FFE-26F0-42AA-AF87-FCA70E72B77FQ37737327-F22D769A-F0E4-4DCD-8EB6-F410AA43881BQ37783631-E49B7BEF-6262-4CB9-BBFE-E1644A802457Q37849976-7413BB1F-286B-4466-8B84-A1FBB4479751Q37854072-DF4FAF07-DBCF-4B8F-88DA-66610C9BDB0AQ38053489-0016F0C5-D2BF-4598-9251-262AD63526ABQ38148588-83BF14F1-C38E-4E79-98DA-036E7D8D6E6AQ38159805-45525DF5-B54B-4ED5-B56D-1B532705FB28Q38183420-45A20E6D-59A3-412C-9CC4-17AAC54B4381Q38314204-09EE8899-33C0-490D-80FB-2E4A04C5FEDCQ38403243-768BD663-B285-4789-9F63-B4C3A474F5E1Q38435424-4A91523A-0EF4-46E0-86D8-CF900790A32AQ38574574-2794ADE8-4D74-440A-A72E-2775DFE1CB10Q38662760-2A8BA18C-6672-4F29-8194-5B7A9F70DDF3Q38842168-6DFB6A7B-014A-4A07-B90A-BBA0B3D0B0E0Q38948541-F32C1187-E75A-4E6E-A9A9-519ADC050559Q39247530-064BE9EB-B55C-4DD7-93B1-501C720C871D
P2860
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Intratumor heterogeneity of ca ...... ted by 5-aza-2'-deoxycytidine.
@en
type
label
Intratumor heterogeneity of ca ...... ted by 5-aza-2'-deoxycytidine.
@en
prefLabel
Intratumor heterogeneity of ca ...... ted by 5-aza-2'-deoxycytidine.
@en
P2093
P50
P1433
P1476
Intratumor heterogeneity of ca ...... ted by 5-aza-2'-deoxycytidine.
@en
P2093
Catia Traversari
Ester Fonsatti
Francesca Colizzi
Luca Sigalotti
Maresa Altomonte
Silvia Tanzarella
P304
P356
10.1158/0008-5472.CAN-04-1442
P407
P577
2004-12-01T00:00:00Z